Ligand Pharmaceuticals Incorporated
Price
OptionsOpen the Sheet →FilingsNewest: 8-K, Regulation FD disclosureSep 24 →InsidersNo open-market buys. 8 insiders sold $17.1M, 82 of 99 sales on a 10b5-1 plan.→HoldersBlackRock 15.6%Invesco 6.0%Vanguard Portfolio 5.7%→Financing →PeersClosest companies: ZYME, BCRX, INCY→
From the filings
Figures
- Revenue
- $290.5Mlast 12 months
- Net income
- $197.2Mlast 12 months
- Operating cash flow
- $123.5Mlast 12 months
- Cash and equivalents
- $1.01Bat the last balance sheet
- Total debt
- $1.13Bat the last balance sheet
- Shares outstanding
- 19.9M shareson issue